# US 10,245,309 B2 · Antigen specific multi epitope-based anti-infective vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,309 B2
- Document ID: US10245309B2
- Status: Granted
- Kind: B2
- Application number: 15/588,887
- Filed: 2017-05-08
- Published: 2017-12-14
- Granted: 2019-04-02
- Earliest claimed: 2009-07-16
- Assignees: Lior Carmon; Vaxil Biotherapeutics Ltd.
- Applicants: Lior Carmon; Vaxil Biotherapeutics Ltd.
- Inventors: Lior Carmon
- Web page: https://patentgrep.com/patent/US10245309B2

## CPC

- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 37/04: Immunostimulants
- A61K 2039/6031: {Proteins}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- A61K 2039/6075: {Viral proteins}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

## Claims

### Claim 1

A method of treating a pathogenic infection in a subject in need thereof, comprising administering to the subject any one of:
(i) an immunogenic composition comprising at least one peptide comprising a signal peptide domain of at least one target protein of said pathogen, wherein said peptide is not longer than 40 amino acids;
(ii) an enriched T cell population obtained by administering an immunogenic composition comprising at least one peptide comprising a signal peptide domain of at least one target protein of said pathogen to a T cell population in vitro, wherein said peptide is not longer than 40 amino acids.

### Claim 2 (depends on 1)

The method of claim 1, wherein said signal peptide domain comprises SEQ ID NO: 12.

### Claim 3 (depends on 1)

The method of claim 1, wherein said pathogen is selected from the group consisting of: Tuberculosis, Malaria, Toxoplasma, Epstein Bar Virus (EBV), Human Immunodeficiency Virus (HIV), Herpes Virus, and Influenza.

### Claim 4 (depends on 3)

The method of claim 3, wherein said pathogen is Tuberculosis and said target protein is selected from the group of Tuberculosis antigens consisting of: BPBP1, Antigen 85B, Antigen 85B-Precursor, Lipoprotein IpqH, Putative lipoprotein IprB precursor, Putative lipoprotein IpqV precursor, Beta gluconase putative, Hypothetical protein MTO 213, Protease, ATP dependent helicase putative, Hypothetical protein MT1221, BCG, Hypothetical protein Rv0476/MT04941 precursor Hypothetical protein Rv1334/MT1376 precursor, and beta-Lactomase precursor.

### Claim 5 (depends on 3)

The method of claim 3, wherein said pathogen is Malaria and said target protein is selected from the group of Malaria antigens consisting of: Circumsporozoit protein precursor, Malaria exported protein-1, Liver stage antigen (LSA-1), Sporozoit surface antigen 2, MSP1, Protein Antigen, Cytoadherence linked asexual protein, Membrane protein PF12, Exported protein 2, Circumsporozoite-protein related antigen, Circumsporozoite protein precursor, Merozoite surface protein 3 alpha, and CTRP adhesive protein invasive stage.

### Claim 6 (depends on 3)

The method of claim 3, wherein said pathogen is Toxoplasma and said target protein is selected from the group of Toxoplasma antigens consisting of: GRA-1, SAG1, Surface antigen SAG1, Surface antigen P22, and Rhoptry protein 10.

### Claim 7 (depends on 3)

The method of claim 3, wherein said pathogen is EBV and said target protein is selected from the group of EBV antigens consisting of: Glycoprotein GP85 and BCRF-1, the CMV antigens, Glycoprotein B, RAE-1 (human), Unique short US8 glycoprotein precursor, US9 Protein, US7; and the human Prion protein.

### Claim 8 (depends on 3)

The method of claim 3, wherein said pathogen is HIV and said target protein is selected from the group of HIV antigens consisting of: Envelope Glycoprotein, reticulocalbin-2 precursor (human), neuronalacetycholine receptor alpha 3 (human), Envelope polyprotein GP '160 precursor and Transforming membrane receptor-like protein.

### Claim 9 (depends on 3)

The method of claim 3, wherein said pathogen is Herpes Virus and said target protein is HHV-8 glycoprotein E8-1.8.

### Claim 10 (depends on 3)

The method of claim 3, wherein said pathogen is Influenza and said target protein is selected from the group of Influenza antigens consisting of: Hemagglutenin precursor, Neuraminidase, the human HCV related protein CEP and Angioprotein 1 receptor precursor.

### Claim 11

A method of activating both CD4+ and CD8+ T cells, comprising administering an immunogenic composition comprising at least one peptide comprising a signal peptide domain of at least one target protein of an intracellular pathogen to said T cells, wherein said peptide is not longer than 40 amino acids.

### Claim 12 (depends on 11)

The method of claim 11, wherein said signal peptide domain comprises SEQ ID NO: 12.

### Claim 13 (depends on 11)

The method of claim 11, wherein said pathogen is selected from the group consisting of: Tuberculosis, Malaria, Toxoplasma, Epstein Bar Virus (EBV), Human Immunodeficiency Virus (HIV), Herpes Virus, and Influenza.

### Claim 14 (depends on 13)

The method of claim 13, wherein said pathogen is Tuberculosis and said target protein is selected from the group of Tuberculosis antigens consisting of: BPBP1, Antigen 85B, Antigen 85B-Precursor, Lipoprotein IpqH, Putative lipoprotein IprB precursor, Putative lipoprotein IpqV precursor, Beta gluconase putative, Hypothetical protein MTO 213, Protease, ATP dependent helicase putative, Hypothetical protein MT1221, BCG, Hypothetical protein Rv0476/MT04941 precursor Hypothetical protein Rv1334/MT1376 precursor, and beta-Lactomase precursor.

### Claim 15 (depends on 13)

The method of claim 13, wherein said pathogen is Malaria and said target protein is selected from the group of Malaria antigens consisting of: Circumsporozoit protein precursor, Malaria exported protein-1, Liver stage antigen (LSA-1), Sporozoit surface antigen 2, MSP1, Protein antigen, Cytoadherence linked asexual protein, Membrane protein PF12, Exported protein 2, Circumsporozoite-protein related antigen, Circumsporozoite protein precursor, Merozoite surface protein 3 alpha, and CTRP adhesive protein invasive stage.

### Claim 16 (depends on 13)

The method of claim 13, wherein said pathogen is Toxoplasma and said target protein is selected from the group of Toxoplasma antigens consisting of: GRA-1, SAG1, Surface antigen SAG1, Surface Antigen P22, and Rhoptry protein 10.

### Claim 17 (depends on 13)

The method of claim 13, wherein said pathogen is EBV and said target protein is selected from the group of EBV antigens consisting of: Glycoprotein GP85 and BCRF-1, the CMV antigens, Glycoprotein B, RAE-1 (human), Unique short US8 glycoprotein precursor, US9 Protein, US7; and the human Prion protein.

### Claim 18 (depends on 13)

The method of claim 13, wherein said pathogen is HIV and said target protein is selected from the group of HIV antigens consisting of: Envelope Glycoprotein, reticulocalbin-2 precursor (human), neuronalacetycholine receptor alpha 3 (human), Envelope polyprotein GP '160 precursor and Transforming membrane receptor-like protein.

### Claim 19 (depends on 13)

The method of claim 13, wherein said pathogen is Herpes Virus and said target protein is HHV-8 glycoprotein E8-1.8.

### Claim 20 (depends on 13)

The method of claim 13, wherein said pathogen is Influenza and said target protein is selected from the group of Influenza antigens consisting of: Hemagglutenin precursor, Neuraminidase, the human HCV related protein CEP and Angioprotein 1 receptor precursor.